Blog

Prerna Mewawalla: Real-world outcomes of sequential BCMA-directed therapy in Multiple Myeloma

Prerna Mewawalla/findcare.ahn.org

Mar 10, 2025, 08:25

Prerna Mewawalla: Real-world outcomes of sequential BCMA-directed therapy in Multiple Myeloma

Prerna Mewawalla, Associate Professor at Drexel University, shared a post on X:

“My VuMedi presentation from Tandem2025 is live!

We explore real-world outcomes of sequential BCMA-directed therapy in Multiple Myeloma from the USMIRC study—highlighting the feasibility of CAR-T & bispecifics post-BCMA exposure.

Key insights from our research:

Sequential BCMA therapy remains feasible and effective.
No significant difference in PFS between CAR-T and bispecifics following Belantamab.
Prior BCMA exposure did not predict poor outcomes.

Would love to hear your experiences with BCMA sequencing in practice—how are you approaching it?

Watch here.”

belantamab cancer CAR-T Drexel University fight against cancer Global fight against cancer multiple myeloma OncoDaily Oncology Prerna Mewawalla Tandem2025 USMIRC study

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial

John Cena Announces He Overcame Skin Cancer Twice, Advocates for Sun Safety

William N. Hait to Receive 2025 AACR-Margaret Foti Award for Leadership in Cancer Research